Skip to content 
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York. more
| Time Frame | CURX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 5.3% | 0.72% | -1.31% |
| 1-Month Return | -21.99% | 1.27% | 0.78% |
| 3-Month Return | -40.4% | 3.13% | 3.46% |
| 6-Month Return | -92.59% | 15.81% | 6.19% |
| Dec '22 | Dec '23 | Dec '24 | ||||
|---|---|---|---|---|---|---|
| Total Revenue | 26.00K | - | - | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Cost of Revenue | 21.57K | - | - | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Gross Profit | 4.43K | - | - | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Gross Margin | 17.03% | - | - | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Operating Expenses | 24.66K | 19.30K | 365.06K | [{"date":"2022-12-31","value":6.76,"profit":true},{"date":"2023-12-31","value":5.29,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | ||
| Operating Income | (20.23K) | (19.30K) | (365.06K) | [{"date":"2022-12-31","value":-2023300,"profit":false},{"date":"2023-12-31","value":-1929800,"profit":false},{"date":"2024-12-31","value":-36506200,"profit":false}] | ||
| Total Non-Operating Income/Expense | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Pre-Tax Income | (20.23K) | (19.20K) | (361.51K) | [{"date":"2022-12-31","value":-2023300,"profit":false},{"date":"2023-12-31","value":-1919800,"profit":false},{"date":"2024-12-31","value":-36150600,"profit":false}] | ||
| Income Taxes | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Income After Taxes | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Income From Continuous Operations | (20.23K) | (19.20K) | (361.51K) | [{"date":"2022-12-31","value":-2023300,"profit":false},{"date":"2023-12-31","value":-1919800,"profit":false},{"date":"2024-12-31","value":-36150600,"profit":false}] | ||
| Income From Discontinued Operations | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Net Income | (20.23K) | (19.20K) | (361.51K) | [{"date":"2022-12-31","value":-2023300,"profit":false},{"date":"2023-12-31","value":-1919800,"profit":false},{"date":"2024-12-31","value":-36150600,"profit":false}] | ||
| EPS (Diluted) | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
| CURX | |
|---|---|
| Cash Ratio | 31.35 |
| Current Ratio | 77.53 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CURX | |
|---|---|
| ROA (LTM) | -30.03% |
| ROE (LTM) | -85.25% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CURX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.01 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.99 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CURX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.56 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Curanex Pharmaceuticals Inc Common Stock (CURX) share price today is $0.298
Yes, Indians can buy shares of Curanex Pharmaceuticals Inc Common Stock (CURX) on Vested. To buy
Yes, you can purchase fractional shares of Curanex Pharmaceuticals Inc Common Stock (CURX) via the Vested app. You can start investing in Curanex Pharmaceuticals Inc Common Stock (CURX) with a minimum investment of $1.
You can invest in shares of Curanex Pharmaceuticals Inc Common Stock (CURX) via Vested in three simple steps:
The 52-week high price of Curanex Pharmaceuticals Inc Common Stock (CURX) is $9.18. The 52-week low price of Curanex Pharmaceuticals Inc Common Stock (CURX) is $0.26.
The price-to-earnings (P/E) ratio of Curanex Pharmaceuticals Inc Common Stock (CURX) is
The price-to-book (P/B) ratio of Curanex Pharmaceuticals Inc Common Stock (CURX) is 0.56
The dividend yield of Curanex Pharmaceuticals Inc Common Stock (CURX) is 0.00%
The market capitalization of Curanex Pharmaceuticals Inc Common Stock (CURX) is $7.99M
The stock symbol (or ticker) of Curanex Pharmaceuticals Inc Common Stock is CURX
Consider the share price of Curanex Pharmaceuticals Inc Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Curanex Pharmaceuticals Inc Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Curanex Pharmaceuticals Inc Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Curanex Pharmaceuticals Inc Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Curanex Pharmaceuticals Inc Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Curanex Pharmaceuticals Inc Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
